Life Insurance With Arthritis or Osteoporosis

Last reviewed August 2026 by Dev Gaymes, Licensed Insurance Advisor · Editorial policy

Arthritis and osteoporosis get lumped together as “bone and joint problems.” Underwriters do not see them that way. Osteoarthritis is priced on almost nothing. Rheumatoid arthritis is priced on cardiovascular risk. Osteoporosis is priced on fractures, not on your T-score. Knowing which file you are in changes what to expect.

Osteoarthritis vs rheumatoid arthritis

These are the two most commonly confused, and the difference in outcome is substantial.

	Osteoarthritis	Rheumatoid arthritis
What it is	Mechanical joint degeneration - wear and tear	Systemic autoimmune disease
Effect on mortality	Does not directly increase mortality risk	Carries associated cardiovascular risk - this is the actual underwriting concern
Typical outcome	Standard or better is the norm, not the exception	Standard is commonly the best available; ratings above that are frequent
Joint replacements	Even multiple replacements routinely reach Standard or Preferred once recovery is complete	Assessed alongside overall disease control
What triggers a rating	Severe functional impairment, ongoing high-dose opioid use, or surgery within 6-12 months	Disease activity, medication regimen, inflammatory markers, functional status

General industry patterns, not promises. Individual outcomes depend on your full profile and the carrier's guidelines when you apply.

The thing most people get wrong about rheumatoid arthritis. Underwriters are not primarily worried about your joints. They are worried about the cardiovascular risk that travels with systemic inflammation - and for older applicants, cardiovascular risk factor control is frequently more impactful on the outcome than the arthritis itself. An applicant with well-managed RA, good blood pressure, controlled lipids, healthy weight and no tobacco use gets materially better terms than one with the same RA and poor cardiovascular control.

Medication tells the underwriter how severe it is

Medication	How it is generally viewed
NSAIDs, acetaminophen	Essentially no rating impact
DMARDs such as methotrexate	Mild to moderate - indicates active management
Biologics (adalimumab, etanercept and similar)	Signals moderate-to-severe disease, but stable long-term use can strengthen a file
Long-term high-dose corticosteroids	Unfavorable - sustained doses above roughly 20mg daily of prednisone raise bone density and infection concerns
Bisphosphonates, denosumab	Neutral to positive for osteoporosis - evidence of active treatment
Ongoing opioid pain medication	Consequential - see the pain medication section on our back and spine page

General descriptions of how medication classes are commonly assessed. Not medical advice, not any specific carrier's guidelines, and not a reason to change a prescription.

Biologics are not the negative people assume. Being on adalimumab or etanercept indicates more significant disease than methotrexate alone, which draws a closer look. But stable long-term biologic therapy can strengthen a case - it reads as consistent modern management rather than uncontrolled progression. What concerns underwriters more is a history of multiple medication failures, or active symptoms continuing despite advanced treatment.

Inflammatory markers matter for RA and psoriatic arthritis

Underwriters look for objective evidence of disease activity, not just the diagnosis and the prescription. ESR, CRP, rheumatoid factor and anti-CCP antibodies come up routinely in review.

Consistent rheumatology follow-up showing stable, normal or trending-down markers supports a much stronger case than one where markers are elevated or poorly tracked. If you have recent labs, bring them - it is one of the few things on these files entirely within your control.

Osteoporosis is priced on fractures, not T-scores

This is the finding that surprises people most. The diagnosis itself carries relatively minor underwriting implications. What matters is whether it has broken anything.

Situation	Common outcome
Osteopenia (T-score -1 to -2.5), no fracture	Generally no rating impact
Osteoporosis (T-score below -2.5), no fracture, on treatment	Standard is typical
Stable or improving bone density on therapy	Supports the case - treatment response is what underwriters want to see
One prior fragility fracture	Modest loading reflecting elevated future fracture risk
Multiple fractures, or severe spinal compression	Assessed more carefully
Hip fracture history	Weighted most heavily - hip fractures carry the highest associated mortality risk
Secondary osteoporosis (steroid-induced, celiac, hyperparathyroid)	Assessed on both the bone disease and the underlying cause

General industry patterns. T-score thresholds follow standard WHO definitions: normal above -1, osteopenia -1 to -2.5, osteoporosis below -2.5. Outcomes depend on your full profile and the carrier.

Treatment compliance is a positive signal here. Unlike some conditions where medication implies severity, being on a bisphosphonate or denosumab with stable or improving bone density reads well. It demonstrates the condition is identified, treated and responding. Untreated osteoporosis with declining density is the harder file.

What to have ready

Which condition, specifically. Osteoarthritis, rheumatoid, psoriatic, osteopenia or osteoporosis. People say “arthritis” without knowing which, and it changes the file entirely.
Recent inflammatory markers and your last rheumatology visit date, for RA or psoriatic arthritis.
Your most recent DEXA result and the date, for osteoporosis - plus the previous one if you have it, since the trend matters more than the number.
Fracture history - what, when, and how it happened.
Every medication with dose and prescriber, including how long you have been on the current regimen.
An honest account of function. Working, exercising and living independently is heavily weighted and consistently under-reported.

Where carrier choice earns its keep

Carriers diverge sharply on inflammatory arthritis. One company may treat stable rheumatoid arthritis on a biologic as a manageable Standard case while another applies a table rating to the same file. Osteoporosis without fracture is more uniform, but fracture history is not. Rates are filed with state regulators, so the premium is identical whether you buy direct or through a broker. What changes is whether anyone matched your file to a carrier whose guidelines fit it.

Related: Back pain and spine surgery if that also applies, blood pressure - which matters more on an RA file than most people realize - and a Dallas guide to impaired risk.

Frequently Asked Questions

Can I get life insurance with arthritis?

Almost always, and often at better rates than expected. Osteoarthritis is degenerative wear and tear that does not directly increase mortality risk, and well-managed cases - including some with multiple joint replacements behind them - routinely qualify for Standard or better once recovery is complete. Rheumatoid arthritis is assessed more carefully because it is systemic, but coverage is widely available and stable, well-treated cases commonly reach Standard.

Why is rheumatoid arthritis underwritten more strictly than osteoarthritis?

Because of cardiovascular risk rather than joint damage. Rheumatoid arthritis is a systemic autoimmune condition, and the inflammation associated with it carries elevated cardiovascular risk. That is what underwriters are pricing. Osteoarthritis is mechanical joint degeneration with no comparable systemic effect. Two people with similar daily pain from these two conditions can receive completely different offers.

Does being on a biologic like Humira or Enbrel hurt my application?

It signals moderate-to-severe disease, which draws a closer look, but stable biologic therapy can actually strengthen a file. Underwriters want evidence of consistent long-term management - regular rheumatology follow-up, inflammatory markers that are normal or trending down, and good functional status. What concerns them is a pattern of multiple medication failures or symptoms continuing despite advanced treatment.

Does osteoporosis affect life insurance rates?

Less than most people expect, if you have not had a fracture. Uncomplicated osteoporosis found through routine screening, with treatment in place and stable or improving bone density, typically qualifies for Standard or better. The diagnosis itself carries relatively minor implications - what changes the assessment is fracture history.

Does my DEXA T-score determine my rate?

Not on its own. Underwriters look at bone density trends over time and fracture history rather than fixating on a single T-score. A stable or improving reading on treatment supports the case; a declining one without treatment is the harder file. Bringing your two most recent DEXA results is more useful than bringing just the latest.

What if I have had a fracture?

It depends on which one and how many. A single fragility fracture typically attracts a modest loading reflecting elevated future fracture risk. Multiple fractures or severe spinal compression are assessed more carefully. Hip fracture history is weighted most heavily, because hip fractures carry the highest associated mortality risk of the osteoporotic fractures.

Do joint replacements affect my rate?

Usually not, once recovery is complete. Even applicants with multiple joint replacements routinely reach Standard or Preferred, provided overall health is good and function has returned. The main exception is a very recent replacement - within roughly six to twelve months - where carriers typically want recovery confirmed before assessing.

Does having both arthritis and osteoporosis compound the assessment?

It can, particularly where long-term corticosteroid use links them - sustained steroid therapy for inflammatory arthritis is a recognized cause of secondary osteoporosis, and an underwriter reading both conditions plus steroid history assesses them as one connected picture rather than separately. Where the two are unrelated and both well managed, the compounding is usually modest.

Dev Gaymes is a licensed insurance broker, not a physician. General education, not medical advice and not advice about your situation, and not an offer of insurance or a quote. Never change, reduce or stop any prescribed medication for an insurance application or for any reason other than your physician’s direction. Clinical thresholds and medication names are referenced generically to describe how classes of treatment are commonly assessed; nothing here evaluates any treatment’s appropriateness for you. Underwriting guidelines vary by carrier, product and state, change over time, and are applied case by case at the underwriter’s discretion. All coverage is subject to carrier underwriting approval, and policy terms, benefits, exclusions and limitations are governed solely by the issued policy contract. Always answer every application question completely and truthfully.